Teva says a US district court victory that has seen the company successfully invalidate four patents protecting Adapt Pharma’s Narcan (naloxone) nasal spray may clear the way for it to launch its approved generic version of the opioid overdose treatment.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?